Why Attend
Following the success of our first digital event in July with the likes of Carl June leading the keynote, the Onco Cell Therapy Summit is returning in its most interactive form ever with 20+ panel conversations, townhall meetings, roundtable sessions and coffee break style networking.
The Global Onco Cell Therapy Summit provides a platform for information sharing to enable the discovery, translation and commercialization of cell therapies in oncology by connecting senior representatives in pharma, biotechs and academia. The summit will address the research, regulatory, logistical and technical challenges that are holding back the field.
Delve into how thought leaders in cell therapy are addressing threats and opportunities to bring effective therapies to the market through:
- Meeting efficacies and safety targets as well as the scale of demands.
- Discovering the latest advances in the journey towards effective allogeneic and solid tumor targeting therapies.
- Overcoming the challenging in scale up and automation of manufacturing
- Round table discussions on vectors and the promise of non-viral approaches.
- Reimbursment strategies and their link to the latest developments in safety trials and regulatory standards
Whilst bringing together the key decision makers for oncological cell therapies, this year’s summit will have an added focus on the data releases and mergers that are driving the surge of interest in harnessing alternative cell therapies in cancer treatments.
Mission Statement
With 5 CAR-T therapies now approved, the cell therapy market is starting to move through its nascent stages. As of the start of 2021, there are another 23 candidates in phase III clinical trials. As the competition between approved cell therapies becomes available to patients, differentials in price and efficacy become front of mind.
The Onco Cell Therapy Summit returns to the EU in 2022 to address issues in scale-up and out of next-generation therapies and explore the translation of R&D through the clinic to revolutionize patient outcomes in oncology.
2021 Speakers
Adrian Bot
Dr. Christina Coughlin
Michael Hudecek
Jason Litten
Dan Kaufman
Alice Brown
John Rossi
Dr Detlev Parow
Evren Alici
Prof. Torsten Tonn
Deepak Raj
Nick Huntington
Blake Aftab
James Patterson
Frank Thielmann
Eytan Breman
Tony Ho
Steven Kanner
Hong Ma
Hanspeter Gerber
Volker Huppert
Robert Kochl
Darrell Irvine
Professor Graham Pockley
Stephen Feldman
Dr John Maher
Reagan Jarvis
Professor Ann Ager
Paul Rennert
Dan Shelly
Kenneth Warrington
Ken Warrington, PhD joined GenScript Probio in 2020 as Head of Strategy & Innovation and a Sr. Director of Business Development supporting their Gene & Cell Therapy CMC services. Dr. Warrington served on the faculty at the University of Florida focused on AAV vector development and transitioned into industry where he has served lead technical operation and business development roles for global contract testing and manufacturing organizations. He is a co-founder and director of Lacerta Therapeutics and Chair of the Scientific Advisory Board at Biostem Life Sciences. He has broad expertise across the viral vector product development continuum from discovery through GMP-compliant manufacturing to support IND-enabling preclinical and early stage clinical programs.
Dr. Avery Posey
Marie Berger
WHO WILL BE THERE
Network with industry experts from:
- Big pharma and biotech
- Cell Therapy Academics and clinicians
- Process standardisation - technology/services
- Logistics companies - cell storage/transport
- Service providers - CRO’s, Consultants, Government
Past attendees include:
2021 Agenda
Please fill in your details to download the Sample Agenda of 5th Annual OCTS Agenda. The OCTS EU 2022 Agenda is launching soon.
Last year OCTS Global ran as two seperate events, CAR-T Congress EU and Vein-to-Vein EU. Take a look at the highlights and what people thought of the event.
Download agenda
2021 Expertise Partners
Miltenyi Biotec
Website: www.miltenyibiotec.com
At Miltenyi Biotec, we are committed to enabling the delivery of new cell and gene therapy (CGT) treatment options to patients with unmet medical needs. We develop tailored cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable fully closed and automated manufacturing of complex CGT products. In addition, we offer contract development and GMP manufacturing of CGT products as well as design, development, and production of tailored GMP lentiviral vectors
Genscript Probio
Website: https://www.genscriptprobio.com/
GenScript ProBio is the bio-pharmaceutical CDMO segment of the world's leading biotech company GenScript Biotech Corporation (Stock Code: 1548.HK). Founded in 2002 in New Jersey, GenScript started business from gene synthesis. Now, GenScipt ’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
In Jan 2019, GenScript established the Biologics Development Business Unit (BDBU) which is the predecessor of GenScript ProBio.
The name of "ProBio" indicates 3 core philosophies - being PROACTIVE, PROFESSIONAL and PROCESS-oriented. GenScript ProBio shows our dedication to proactively provide end to end service (discovery to commercialization) with professional solutions, and efficient process to accelerate drug development for customers.
GenScript ProBio has established the integrated innovative biologics CDMO platforms, covering two major service areas: therapeutic antibody drug and gene & cell therapy. We are committed to driving innovation and accelerating biologics development from target to market.
GenScript ProBio's one-stop antibody drug development solutions include antibody drug discovery (hybridoma, phage display, single B cell, fully human and bispecific antibody technologies), antibody engineering (antibody humanization, affinity maturation, developability assessment and optimization), antibody development (stable cell line generation, process development), and clinical and commercial manufacturing. GenScript ProBio's integrated GCT solution covers IND preparation as well as clinical sample and commercial production. Process development quality systems ensure compliance, data integrity and traceability, and all test deviations are strictly studied and documented. With the principle of "providing the best-in-class quality to and serving the interests of customers", GenScript ProBio is committed to helping customers to shorten the timeline for biological drugs from development to clinical use, significantly cutting down the R&D costs, accelerating the commercialization of medicines, and building a healthy future while making contributions to the development of the pharmaceutical industry.
2021 Tech Showcase Partner
Myriade
Website: http://www.myriadelab.com/en/
Myriade is a French company created in 2017 that develops an innovative nanoscale imaging technology: the VIDEODROP
Based on the principles of interferometry, the Videodrop makes it possible to visualize living nanoparticles in the range of 30 nm and 10 microns without labeling, in real time and in a single drop.
The Videodrop processing algorithms compute the concentration and size distribution of the nanoparticles and enable to analyze complex mixtures of phages (T4, lambda) for applications in phagotherapy, continuously monitor viral vector solutions (Lentiviruses, adenoviruses) for gene and cell therapy, and distinguish the different types of EVs to vectorize, diagnose or treat
2021 Event Partners
Anemocyte
Website: www.anemocyte.com
Anemocyte is a Biotech Manufacturing Organization (BMO); a biotech company active in the field of Cell and Gene Therapies (CGTs) that addresses CGT needs pro-actively offering one stop shop solutions and fostering exciting innovations.
Our business:
- Process development and GMP capabilities (Somatic Cells, Non-Viral Modified Cells, Vesicles)
- Plasmids for Viral Vector Manufacturing.
- Project Exellula: to address up to commercial scale needs for CGTs Including Viral Vectors modified cells.
- Big Data Analysis of CGTs
Our experience:
- More than 15 years of GMP manufacturing of CGTs and biological drugs;
- More than 60 years of Contract Manufacturing within our Group (Nine Trees Group)
Bio-Techne
Website: www.bio-techne.com
Bio-Techne offers a full range of products and services for Targeted Protein Degradation research and development, including: small molecule Protein Degraders (e.g. PROTAC® degraders); aTAG and dTAG Degraders plus custom TAG knock-in cell lines; Degrader Building Blocks, Ubiquitin-Proteasome System Proteins and Assays; Assays for Protein Degradation and Custom Degrader Services.
2021 Media Partners
Gene Therapy Net
Website: www.genetherapynet.com
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
World Pharma Today
Website: https://www.worldpharmatoday.com/
Please visit our website for more information.Pharma Journalist
Website: www.pharmajournalist.com
Pharma Journalist is a leading international B2B magazine providing the global information and the recent updates in the Pharmaceutical Industry.
Our editorial staff works dedicatedly to provide latest information of Pharmaceutical Industry in the form of articles, news, trends, analysis, market report, press releases, whitepapers, case studies, etc. which helps Industry professionals and decision makers to stay on the top of this fast-paced industry.
Various Online marketing services and promotional activities through Pharma Journalist helps companies and organizations to reach their target audience and create brand awareness.
CheckRare
Website: https://checkrare.com/
CheckRare is a learning platform for health care professionals and patients. Our platform allows users to gain insight and learn about rare diseases, current and emerging therapies, clinical trials, and the BioPharma companies behind them. Our peer-to-peer content is a trusted source for education and industry-related content. Our native content and sponsored programs are developed through our website, e-newsletter, social media platforms, and live meetings. We are a trusted, strategic partner with all major organizations in the global network of rare disease advisors and advocates. There is no fee to register on CheckRare and all content is free of charge.
Become a Partner
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.